WASHINGTON, D.C. -- The Centers for Disease Control and Prevention (CDC) is offering a new experimental laboratory test for patients suspected of being infected with the SARS virus to about 100 specialized laboratories around the country.
The experimental diagnostic test was rapidly developed by the CDC during the past few months in an urgent effort to address this pressing public health need. The Food and Drug Administration (FDA) has worked closely with the CDC to develop appropriate information for patients and health professionals in order to make the test available on an investigational basis. Because information about the test's performance is still being collected, patients will be asked for written consent before the test is used.
"Because of the special efforts of the dedicated professionals at these two agencies to respond effectively to SARS, we now have a needed SARS diagnostic test for use at a growing number of laboratories," Health and Human Services Secretary Tommy G. Thompson said. "This experimental test marks a significant step forward in our ability to confront and ultimately overcome this new disease, and its development embodies the commitment of our department to protecting public health."
The new test uses polymerase chain reaction technology to detect evidence of the presence of the coronavirus. Polymerase chain reaction is a way to detect the genetic material of an organism in a couple of hours. The standard method of growing the organism in cell culture takes several days or up to several weeks.
As part of the wider distribution of the new test, patients and practitioners will receive clear information about how the test may assist in diagnosing SARS. The CDC and FDA are also cooperating on further scientific evaluation of the new test's accuracy and reliability.
In addition, through the evaluation of the test in more patients and settings, more will be learned about the accuracy and reliability of the test, and how it can be improved. This information will support the development of approved diagnostic tests as quickly as possible.
Source: CDC
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.